- Home
- HTOO vs JAGX Comparison
HTOO vs JAGX Comparison
Compare HTOO & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTOO
- JAGX
- Stock Information
- Founded
- HTOO 2020
- JAGX 2013
- Country
- HTOO Ireland
- JAGX United States
- Employees
- HTOO N/A
- JAGX N/A
- Industry
- HTOO Natural Gas Distribution
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- HTOO Utilities
- JAGX Health Care
- Exchange
- HTOO Nasdaq
- JAGX Nasdaq
- Market Cap
- HTOO 12.3M
- JAGX 12.9M
- IPO Year
- HTOO N/A
- JAGX N/A
- Fundamental
- Price
- HTOO $0.40
- JAGX $0.86
- Analyst Decision
- HTOO Strong Buy
- JAGX
- Analyst Count
- HTOO 1
- JAGX 0
- Target Price
- HTOO $3.50
- JAGX N/A
- AVG Volume (30 Days)
- HTOO 259.5K
- JAGX 311.0K
- Earning Date
- HTOO 01-01-0001
- JAGX 03-31-2025
- Dividend Yield
- HTOO N/A
- JAGX N/A
- EPS Growth
- HTOO N/A
- JAGX N/A
- EPS
- HTOO N/A
- JAGX N/A
- Revenue
- HTOO $4,440,159.00
- JAGX $10,480,000.00
- Revenue This Year
- HTOO $396.96
- JAGX $18.18
- Revenue Next Year
- HTOO $284.41
- JAGX $40.06
- P/E Ratio
- HTOO N/A
- JAGX N/A
- Revenue Growth
- HTOO N/A
- JAGX N/A
- 52 Week Low
- HTOO $0.28
- JAGX $0.78
- 52 Week High
- HTOO $1.96
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- HTOO 38.82
- JAGX 45.91
- Support Level
- HTOO $0.40
- JAGX $0.78
- Resistance Level
- HTOO $0.46
- JAGX $1.03
- Average True Range (ATR)
- HTOO 0.05
- JAGX 0.07
- MACD
- HTOO -0.01
- JAGX 0.01
- Stochastic Oscillator
- HTOO 13.63
- JAGX 30.44
About HTOO Fusion Fuel Green PLC
Fusion Fuel Green PLC is a company that has developed a Green Hydrogen production technology. It is focused on generating cost-effective and competitively priced Green Hydrogen.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.